Bicara Therapeutics Inc.
BCAX
$18.82
$0.663.63%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 6.66% | -3.15% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 27.04% | -23.38% | |||
| Operating Income | -27.04% | 23.38% | |||
| Income Before Tax | -32.76% | 25.66% | |||
| Income Tax Expenses | -23.08% | -27.78% | |||
| Earnings from Continuing Operations | -32.65% | 25.67% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -32.65% | 25.67% | |||
| EBIT | -27.04% | 23.38% | |||
| EBITDA | -27.04% | 23.39% | |||
| EPS Basic | -32.58% | 25.78% | |||
| Normalized Basic EPS | -32.68% | 25.78% | |||
| EPS Diluted | -32.58% | 25.78% | |||
| Normalized Diluted EPS | -32.68% | 25.78% | |||
| Average Basic Shares Outstanding | 0.05% | 0.15% | |||
| Average Diluted Shares Outstanding | 0.05% | 0.15% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||